Meet Avance Clinical At SCOPE Summit 2026 In Orlando, Florida

February 2 - 5, 2026 | Rosen Shingle Creek, Orlando, FL

Avance Clinical is excited to announce our participation in SCOPE Summit 2026, one of the most influential gatherings in clinical operations, where leading innovators in biotech, pharma, CROs, and technology come together to share strategies shaping the future of global drug development.

Our Business Development team - Cameron Mealey, Clint Henry, and John Mann - will be onsite to meet with biotechs and discuss their complete global drug development pathway, from preclinical readiness to global late-phase success. Book a meeting now.

Partnering with Avance Clinical: Your Full-Service Global CRO for Biotechs

At SCOPE 2026, we invite you to explore how Avance Clinical supports biotechs at every stage of their journey through our integrated suite of solutions and global expertise.

ClinicReady – Guiding Biotechs from Preclinical to First-in-Human

Our ClinicReady service prepares biotechs for a smooth transition from preclinical to clinical development. We help align your preclinical data package, IND-enabling studies, and regulatory strategy — ensuring your first-in-human study is positioned for success. With scientific and regulatory expertise, ClinicReady provides the foundation you need to advance with confidence. Find out more.

Early Phase Excellence – Accelerate Development with Avance Clinical

Avance Clinical is recognized globally for its early-phase capabilities, built on precision, scientific depth, and operational excellence. Our experience spans hundreds of early-phase studies, supporting biotechs in designing adaptive protocols, optimizing timelines, and ensuring quality data that de-risks downstream development. Avance Clinical has more than 30 years of experience in early phase, across more than 250+ therapeutic indications. Find out more.

The Australian Advantage – Faster, Smarter Early Trials

For early-phase biotechs, Australia offers a unique and proven pathway to success - featuring no IND requirement, rapid ethics approval (5–6 weeks), and a 43.5% R&D tax rebate. Avance Clinical’s established operations in Australia and New Zealand enable biotechs to launch clinical trials faster, generate FDA-accepted data, and maximize their investment before expanding globally. Find out more.

GlobalReady – Seamless Transition to Global Late-Phase Trials

Through our GlobalReady program, Avance Clinical guides biotechs as they expand from early-phase trials in Australia into late phase studies, in the United States, Asia, UK and Europe. This integrated approach ensures continuity in data integrity, operational quality, and scientific oversight - minimizing handoff risk and accelerating time-to-market. Find out more.

Late-Phase Expertise – Specialist Knowledge in CNS, Renal & Cardiometabolic, and Oncology

Avance Clinical’s global late-phase team brings deep expertise across complex therapeutic areas; Central Nervous System (CNS), Renal & Cardiometabolic disorders (RCM) and Oncology.

Meet the Avance Clinical Team at SCOPE 2026

Join Cameron Mealey, Clint Henry, and John Mann in Orlando to discuss your biotech’s global development strategy. Whether you’re preparing your first clinical trial or expanding globally, our team will help you chart the most efficient, scientifically sound, and cost-effective path to success.

Let’s meet at SCOPE 2026 to plan your global drug development journey.
Contact us today to schedule a meeting with the Avance Clinical team.